Ponatinib is a third‑generation tyrosine kinase inhibitor (TKI) indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL), particularly in patients with resistance or intolerance to prior therapies. It inhibits cancer cell proliferation by targeting the BCR‑ABL1 protein, including the T315I mutant, and demonstrates significant efficacy in refractory leukemia.
Indications and Mechanism of Action
Indications
For patients with chronic phase, accelerated phase, or blast phase CML, especially those resistant to other TKIs (e.g., imatinib, dasatinib) or harboring the T315I mutation.
For the treatment of Ph+ ALL, particularly when standard therapies are ineffective.
Mechanism of Action
Ponatinib blocks signaling by binding with high affinity to the ATP‑binding site of the BCR‑ABL1 protein, thereby inhibiting leukemic cell growth. Unlike other TKIs, it is active against the T315I mutation, a common resistance mutation, and covers a broad spectrum of mutations.
Efficacy and Clinical Data
In CML Patients
Clinical trials show that approximately 70% of patients with chronic‑phase CML achieve a major cytogenetic response (MCyR), with some attaining complete molecular response (CMR).
In Ph+ ALL Patients
About 40% of patients achieve complete remission. Ponatinib also shows activity against central nervous system leukemia.
In Resistant Patients
Ponatinib is one of the few effective options for patients harboring the T315I mutation.
The above information is for reference only. For specific dosage, administration, and treatment decisions, consult your attending physician.
